PSA Doubling Time

Serial PSA surveillance after treatment — quantifying biochemical recurrence risk

Current Stage

—

—

Current PSA

—

Doubling time

—

Rise rate

—

Aggressiveness

—

PSA rise rate—

Months of follow-up0

Post-treatment nadir

Serial PSA measurement

Fitted exponential rise

Reference PSADT curves

Aggressive recurrence zone

Scroll for details

The Post-Treatment PSA Nadir

Placeholder lead: baseline PSA after successful initial treatment.

<0.2 ng/mL: Typical nadir (placeholder caption text)
~3–6 mo: Time to nadir (placeholder caption text)
0.01 ng/mL: Assay sensitivity (placeholder caption text)
Post-op/RT: Surveillance start (placeholder caption text)

Establishing the baseline

Placeholder body text: nadir sets the reference point for future rises.

Serial PSA Values Over Follow-Up

Placeholder lead: repeated PSA draws build the surveillance trend.

3 mo: Typical interval (placeholder caption text)
0–24 mo: Follow-up window (placeholder caption text)
~10%: Assay variability (placeholder caption text)
≥3: Points needed (placeholder caption text)

Building the trend line

Placeholder body text: multiple points reduce single-assay noise.

PSA Rise Signals Recurrence Before Imaging

Placeholder lead: rising PSA precedes clinical or radiographic findings.

+2 ng/mL: Recurrence threshold (placeholder caption text)
Months–yrs: Lead time vs imaging (placeholder caption text)
2 consecutive: Confirmatory draws (placeholder caption text)
Serial PSA: Detection method (placeholder caption text)

Earliest detectable signal

Placeholder body text: rising trend triggers closer surveillance.

Calculating PSA Doubling Time

Placeholder lead: exponential fit yields the doubling-time estimate.

ln2 / k: Formula (placeholder caption text)
Log-linear: Fit method (placeholder caption text)
<3 mo: Fast PSADT (placeholder caption text)
>12 mo: Slow PSADT (placeholder caption text)

From slope to doubling time

Placeholder body text: growth constant k converts to a doubling interval.

Short vs Long PSADT — Aggressiveness Stratification

Placeholder lead: doubling time guides urgency of intervention.

<3 mo: Short PSADT (placeholder caption text)
>12 mo: Long PSADT (placeholder caption text)
Prompt tx: Aggressive action (placeholder caption text)
Observation: Indolent action (placeholder caption text)

Matching management to risk

Placeholder body text: PSADT stratifies aggressive vs indolent recurrence.

Placeholder highlight: short doubling time warrants prompt clinical action.